Citation

  • Authors: Kveiborg, M., Instrell, R., Rowlands, C., Howell, M., Parker, P. J.
  • Year: 2011
  • Journal: PLoS One 6 e17168
  • Applications: in vitro / siRNA / INTERFERin
  • Cell type: HT-1080
    Description: Human acetabulum fibrosarcoma cells
    Known as: HT1080

Abstract

Epidermal growth factor receptor (EGFR) signalling is initiated by the release of EGFR-ligands from membrane-anchored precursors, a process termed ectodomain shedding. This proteolytic event, mainly executed by A Disintegrin And Metalloproteases (ADAMs), is regulated by a number of signal transduction pathways, most notably those involving protein kinase C (PKC). However, the molecular mechanisms of PKC-dependent ectodomain shedding of EGFR-ligands, including the involvement of specific PKC isoforms and possible functional redundancy, are poorly understood. To address this issue, we employed a cell-based system of PMA-induced PKC activation coupled with shedding of heparin binding (HB)-EGF. In agreement with previous studies, we demonstrated that PMA triggers a rapid ADAM17-mediated release of HB-EGF. However, PMA-treatment also results in a protease-independent loss of cell surface HB-EGF. We identified PKCalpha as the key participant in the activation of ADAM17 and suggest that it acts in parallel with a pathway linking PKCdelta and ERK activity. While PKCalpha specifically regulated PMA-induced shedding, PKCdelta and ERK influenced both constitutive and inducible shedding by apparently affecting the level of HB-EGF on the cell surface. Together, these findings indicate the existence of multiple modes of regulation controlling EGFR-ligand availability and subsequent EGFR signal transduction.

Go to